Fairhaven Wealth Management LLC boosted its position in shares of Amgen, Inc. (NASDAQ:AMGN) by 17.1% during the 1st quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 1,265 shares of the medical research company’s stock after purchasing an additional 185 shares during the period. Fairhaven Wealth Management LLC’s holdings in Amgen were worth $240,000 at the end of the most recent reporting period.
A number of other hedge funds and other institutional investors have also recently bought and sold shares of the business. Saratoga Research & Investment Management grew its position in Amgen by 24.7% during the 1st quarter. Saratoga Research & Investment Management now owns 13,143 shares of the medical research company’s stock worth $2,497,000 after purchasing an additional 2,600 shares in the last quarter. Bowling Portfolio Management LLC grew its position in Amgen by 34.7% during the 1st quarter. Bowling Portfolio Management LLC now owns 15,228 shares of the medical research company’s stock worth $2,893,000 after purchasing an additional 3,923 shares in the last quarter. Sage Rhino Capital LLC purchased a new position in Amgen during the 1st quarter worth approximately $443,000. Providence Wealth Advisors LLC grew its position in Amgen by 4.3% during the 1st quarter. Providence Wealth Advisors LLC now owns 3,539 shares of the medical research company’s stock worth $677,000 after purchasing an additional 147 shares in the last quarter. Finally, Community Bank & Trust Waco Texas grew its position in Amgen by 11.2% during the 1st quarter. Community Bank & Trust Waco Texas now owns 5,831 shares of the medical research company’s stock worth $1,108,000 after purchasing an additional 588 shares in the last quarter. Hedge funds and other institutional investors own 78.01% of the company’s stock.
Shares of NASDAQ:AMGN opened at $172.11 on Friday. The firm has a market cap of $103.50 billion, a price-to-earnings ratio of 11.95, a P/E/G ratio of 2.24 and a beta of 1.15. Amgen, Inc. has a 12-month low of $166.30 and a 12-month high of $210.19. The company has a debt-to-equity ratio of 2.71, a current ratio of 2.77 and a quick ratio of 2.53.
The business also recently announced a quarterly dividend, which will be paid on Friday, June 7th. Shareholders of record on Friday, May 17th will be paid a dividend of $1.45 per share. This represents a $5.80 dividend on an annualized basis and a dividend yield of 3.37%. The ex-dividend date of this dividend is Thursday, May 16th. Amgen’s dividend payout ratio (DPR) is currently 40.28%.
In other Amgen news, Director Ronald D. Sugar sold 2,000 shares of Amgen stock in a transaction on Wednesday, March 6th. The shares were sold at an average price of $188.88, for a total transaction of $377,760.00. Following the completion of the sale, the director now owns 14,988 shares of the company’s stock, valued at approximately $2,830,933.44. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Insiders have sold a total of 6,000 shares of company stock valued at $1,115,580 in the last three months. Company insiders own 0.25% of the company’s stock.
Several equities analysts have weighed in on the stock. Zacks Investment Research cut shares of Amgen from a “buy” rating to a “hold” rating in a research report on Friday, April 5th. Mizuho reiterated a “buy” rating and set a $208.00 price objective on shares of Amgen in a research report on Friday, May 17th. Royal Bank of Canada reiterated a “neutral” rating and set a $192.00 price objective on shares of Amgen in a research report on Tuesday. JPMorgan Chase & Co. reiterated a “hold” rating and set a $190.00 price objective on shares of Amgen in a research report on Wednesday, May 15th. Finally, Credit Suisse Group assumed coverage on shares of Amgen in a research report on Monday. They set an “outperform” rating and a $208.00 price objective on the stock. One investment analyst has rated the stock with a sell rating, nine have assigned a hold rating and eleven have given a buy rating to the company’s stock. The stock currently has an average rating of “Hold” and a consensus price target of $209.05.
COPYRIGHT VIOLATION WARNING: “Amgen, Inc. (AMGN) Shares Bought by Fairhaven Wealth Management LLC” was first reported by Baseball Daily News and is owned by of Baseball Daily News. If you are accessing this story on another site, it was illegally copied and reposted in violation of United States & international copyright and trademark laws. The original version of this story can be accessed at https://www.baseballdailydigest.com/news/2019/05/24/amgen-inc-amgn-shares-bought-by-fairhaven-wealth-management-llc.html.
Amgen Company Profile
Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. It offers products for the treatment of oncology/hematology, cardiovascular, inflammation, bone health, and neuroscience. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta, a pegylated protein to treat cancer patients; Prolia to treat postmenopausal women with osteoporosis; Aranesp to treat anemia; Xgeva for skeletal-related events prevention; Sensipar/Mimpara products to treat sHPT in chronic kidney disease; and EPOGEN to treat a lower-than-normal number of red blood cells.
Further Reading: Does the discount rate affect the economy?
Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen, Inc. (NASDAQ:AMGN).
Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.